195.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BDX Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Becton Dickinson Co Borsa (BDX) Ultime notizie
BD Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with AI-Driven Clinical Decision Support - marketscreener.com
Becton, Dickinson and Company Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with Ai-Driven Clinical Decision Support - marketscreener.com
BD warns on intravascular catheter - MassDevice
Is Becton, Dickinson and Company (BDX) the Best Dividend Monarch to Invest in Now? - Insider Monkey
Is Becton Dickinson Gaining or Losing Market Support? - Benzinga
Global In-Vitro Diagnostics Market Predicted to Surpass the USD 90 Billion Mark by 2032 | DelveInsight - GlobeNewswire Inc.
As historic trial starts in Covington, medical devoce sterilizer defends ‘safe and responsible’ operations - AJC.com
Becton, Dickinson and Co. : Leading Industry Analyst Amit Bhalla Joins BD as Vice President, Global Strategy and Development - marketscreener.com
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports - MSN
Barclays Has Lowered Expectations for Becton, Dickinson and Company (NYSE:BDX) Stock Price - MarketBeat
Retired truck driver contends emissions from ethylene oxide caused his cancer - AJC.com
BD to acquire Bard - The Covington News
Becton, Dickinson and Co. : BD Appoints Christopher Reidy as Chief Financial Officer - marketscreener.com
Becton Dickinson EVP Michael Garrison sells $94,497 in stock - Investing.com Australia
Becton Dickinson EVP Michael Garrison sells $94,497 in stock By Investing.com - Investing.com Canada
Becton Dickinson and : BD Receives FDA 510(k) Clearance for Advanced Microbiology Solution - MarketScreener
Becton Dickinson's SWOT analysis: med tech giant's stock poised for growth - Investing.com
BD Seeks Potential Buyers for Life Sciences Business Division - Yahoo Finance
Citigroup Adjusts Becton Dickinson and Co. Price Target to $270 From $275, Maintains Buy Rating - MarketScreener
Becton, Dickinson Becomes Oversold - Nasdaq
Should You be Confident in Becton, Dickinson and Company’s (BDX) Ability to Deliver Long-Term Returns? - Yahoo
BD reports pay increases for some execs, decreases for others - Medical Design & Outsourcing
BD to Announce Financial Results for its Second Quarter of Fiscal 2025 - Quantisnow
Vascular Access Device Market Growth is Driven by Ongoing Research and Development in the Industry, Key Players -Becton, Dickinson and Company, - Global Banking | Finance | Review
Report: BD is in talks with competitors to sell Life Sciences biz - MassDevice
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports - MarketScreener
Becton Dickinson in talks to divest life sciences unit, FT reports - MarketScreener
Becton Dickinson In Talks With Rivals Over Divesting Life Sciences Unit- FT - marketscreener.com
Becton Dickinson in talks with rivals over divesting life sciences unit - Financial Times
BD Named One of America's Most Innovative Companies by Fortune - Quantisnow
Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline - Seeking Alpha
Here’s What Positions Becton, Dickinson and Company (BDX) Favorably in the Health Care Sector - Yahoo Finance
BD Names Gregory J. Hayes to Board of Directors :: Becton, Dickinson and Company (BDX) - Becton Dickinson
BD Names Gregory J. Hayes to Board of Directors - Quantisnow
BD Names Gregory J. Hayes to Board of Directors – Company Announcement - Financial Times
Goldman Sachs Adjusts PT on Becton Dickinson and Co. to $256 From $253, Keeps Buy Rating - Marketscreener.com
Goldman Sachs Adjusts PT to Becton Dickinson and Co. to $256 From $253, Keeps Buy Rating - marketscreener.com
Was Jim Cramer Right About Becton, Dickinson and Company (BDX)? - Insider Monkey
Insider Sell: Richard Byrd Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus.com
FDA tags Becton, Dickinson and Company infusion software recall as Class I - Yahoo Finance
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Becton Dickinson and : BD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance - MarketScreener
Becton, Dickinson Treats First Breast Revision Patient in GalaFlex Lite Scaffold Trial -March 20, 2025 at 07:56 am EDT - MarketScreener
BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery - Quantisnow
Becton, Dickinson and Company Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE? Scaffold in Breast Implant Revision Surgery - Marketscreener.com
Correction: Software for Alaris Systems Manager and CCE Adapter - fda.gov
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):